NCT06606366 Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
| NCT ID | NCT06606366 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Antoine Lacassagne |
| Condition | Neoplasm Malignant |
| Study Type | INTERVENTIONAL |
| Enrollment | 238 participants |
| Start Date | 2025-03-03 |
| Primary Completion | 2027-06-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 238 participants in total. It began in 2025-03-03 with a primary completion date of 2027-06-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.
Eligibility Criteria
Inclusion Criteria: * Over 18 years old. * Advanced-stage malignant solid tumor managed in a non-curative context. * Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion. * Patient able to read, write, and understand the French language. * Patient has read the information sheet and signed the informed consent. * Patient has social security coverage. Exclusion Criteria: * Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder. * Severe or uncontrolled systemic disease. * Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures. * Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8: * Pregnant women, women in labor, and breastfeeding mothers, * Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8, * Persons admitted to a healthcare or social institution for reasons other than research, * Adults unable to give their consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06606366 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasm Malignant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06606366 currently recruiting?
Yes, NCT06606366 is actively recruiting participants. Contact the research team at DRCI-Promotion@nice.unicancer.fr for enrollment information.
Where is the NCT06606366 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT06606366 clinical trial?
NCT06606366 is sponsored by Centre Antoine Lacassagne. The trial plans to enroll 238 participants.